148 related articles for article (PubMed ID: 38441601)
1. Comparison of DNA damage in granulosa cells of women undergoing controlled ovarian stimulation in in vitro fertilization protocols with the recombinant human follicle-stimulating hormones Corneumon
Alcalá-Sánchez X; Cuapio-Padilla P; Salazar-López C; Rodríguez R; Teteltitla M; Bahena I; Betancourt M; Casas E; Casillas F; López A; Bonilla E
Arch Gynecol Obstet; 2024 May; 309(5):2107-2114. PubMed ID: 38441601
[TBL] [Abstract][Full Text] [Related]
2. Comparison of two recombinant follicle-stimulating hormone preparations in in-vitro fertilization: a randomized clinical study.
Tulppala M; Aho M; Tuuri T; Vilska S; Foudila T; Hakala-Ala-Pietilä T; Moilanen J; Bützow T; Kaukoranta S; Söderström-Anttila V; Siegberg R; Suikkari AM; Hovatta O
Hum Reprod; 1999 Nov; 14(11):2709-15. PubMed ID: 10548606
[TBL] [Abstract][Full Text] [Related]
3. Recombinant follicle-stimulating hormone and recombinant luteinizing hormone versus recombinant follicle-stimulating hormone alone during GnRH antagonist ovarian stimulation in patients aged ≥35 years: a randomized controlled trial.
Vuong TN; Phung HT; Ho MT
Hum Reprod; 2015 May; 30(5):1188-95. PubMed ID: 25740882
[TBL] [Abstract][Full Text] [Related]
4. Safety of Ovaleap® (Follitropin Alfa) in Infertile Women Undergoing Superovulation for Assisted Reproductive Technologies: A Multinational Comparative, Prospective Cohort Study.
Kaplan S; Levy-Toledano R; Davies M; Roy D; Howles CM; Lass A
Front Endocrinol (Lausanne); 2021; 12():632674. PubMed ID: 33815290
[TBL] [Abstract][Full Text] [Related]
5. Recombinant follicle stimulating hormone in in-vitro fertilization treatment-clinical experience with follitropin alpha and follitropin beta.
Harlin J; Csemiczky G; Wramsby H; Fried G
Hum Reprod; 2000 Feb; 15(2):239-44. PubMed ID: 10655291
[TBL] [Abstract][Full Text] [Related]
6. Comparison of recombinant human FSH biosimilar QL1012 with Gonal-f® for ovarian stimulation: a phase-three trial.
Hu L; Lv J; Ma Q; Chen X; Wang X; Liang X; Xu D; Li Y; Huang Y; Hu L; Deng X; Wei J; Zhou F; Zhang S; Wang J; Ma F; Sun Y
Reprod Biomed Online; 2023 Mar; 46(3):511-518. PubMed ID: 36621365
[TBL] [Abstract][Full Text] [Related]
7. Efficacy, safety, and immunogenicity of a biosimilar recombinant human follicle-stimulating hormone (Folitime®) vs. Gonal-f® in women undergoing ovarian stimulation for IVF: A randomized, multicenter, evaluator-blinded, non-inferiority study.
Pasqualini A; Ruhlmann C; Botti GA; Estofán DE; Pasqualini S; Inciarte F; Ruhlmann F; Lopez C; Palena C; Klimovsky E; Federico A; Gonzalez E; Cordeiro L; Lago N
JBRA Assist Reprod; 2021 Oct; 25(4):524-532. PubMed ID: 34338481
[TBL] [Abstract][Full Text] [Related]
8. Safety and efficacy of Ovaleap® (recombinant human follicle-stimulating hormone) for up to 3 cycles in infertile women using assisted reproductive technology: a phase 3 open-label follow-up to Main Study.
Strowitzki T; Kuczynski W; Mueller A; Bias P
Reprod Biol Endocrinol; 2016 Jun; 14(1):31. PubMed ID: 27287439
[TBL] [Abstract][Full Text] [Related]
9. Randomized, active-controlled, comparative phase 3 efficacy and safety equivalence trial of Ovaleap® (recombinant human follicle-stimulating hormone) in infertile women using assisted reproduction technology (ART).
Strowitzki T; Kuczynski W; Mueller A; Bias P
Reprod Biol Endocrinol; 2016 Jan; 14():1. PubMed ID: 26733057
[TBL] [Abstract][Full Text] [Related]
10. Delivery rates following IVF treatment, using two recombinant FSH preparations for ovarian stimulation.
Harlin J; Aanesen A; Csemiczky G; Wramsby H; Fried G
Hum Reprod; 2002 Feb; 17(2):304-9. PubMed ID: 11821268
[TBL] [Abstract][Full Text] [Related]
11. A double-blind, randomized study to compare recombinant human follicle stimulating hormone (FSH; Gonal-F) with highly purified urinary FSH (Metrodin) HP) in women undergoing assisted reproductive techniques including intracytoplasmic sperm injection. The French Multicentre Trialists.
Frydman R; Howles CM; Truong F
Hum Reprod; 2000 Mar; 15(3):520-5. PubMed ID: 10686190
[TBL] [Abstract][Full Text] [Related]
12. Comparison of the efficacy and safety of a new recombinant human follicle-stimulating hormone (DA-3801) with follitropin-alpha (Gonal-F) in women undergoing controlled ovarian hyperstimulation for assisted reproductive technology.
Moon SY; Choi YS; Ku SY; Kim SH; Choi YM; Kang IS; Kim CH
J Obstet Gynaecol Res; 2007 Jun; 33(3):305-15. PubMed ID: 17578360
[TBL] [Abstract][Full Text] [Related]
13. A prospective randomized clinical trial comparing 150 IU and 225 IU of recombinant follicle-stimulating hormone (Gonal-F*) in a fixed-dose regimen for controlled ovarian stimulation in in vitro fertilization treatment.
Yong PY; Brett S; Baird DT; Thong KJ
Fertil Steril; 2003 Feb; 79(2):308-15. PubMed ID: 12568839
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of recombinant follicle stimulating hormone (Puregon) in infertile women pituitary-suppressed with triptorelin undergoing in-vitro fertilization: a prospective, randomized, assessor-blind, multicentre trial.
Hedon B; Out HJ; Hugues JN; Camier B; Cohen J; Lopes P; Zorn JR; van der Heijden B; Coelingh Bennink HJ
Hum Reprod; 1995 Dec; 10(12):3102-6. PubMed ID: 8822422
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and Safety of Pergoveris in Assisted Reproductive Technology--ESPART: rationale and design of a randomised controlled trial in poor ovarian responders undergoing IVF/ICSI treatment.
Humaidan P; Schertz J; Fischer R
BMJ Open; 2015 Jul; 5(7):e008297. PubMed ID: 26141305
[TBL] [Abstract][Full Text] [Related]
16. Urinary hMG (Meropur) versus recombinant FSH plus recombinant LH (Pergoveris) in IVF: a multicenter, prospective, randomized controlled trial.
Pacchiarotti A; Sbracia M; Frega A; Selman H; Rinaldi L; Pacchiarotti A
Fertil Steril; 2010 Nov; 94(6):2467-9. PubMed ID: 20537626
[TBL] [Abstract][Full Text] [Related]
17. The effect of exogenous luteinizing hormone (LH) on oocyte viability: evidence from a comparative study using recombinant human follicle-stimulating hormone (FSH) alone or in combination with recombinant LH for ovarian stimulation in pituitary-suppressed women undergoing assisted reproduction.
Balasch J; Creus M; Fábregues F; Civico S; Carmona F; Puerto B; Casamitjana R; Vanrell JA
J Assist Reprod Genet; 2001 May; 18(5):250-6. PubMed ID: 11464575
[TBL] [Abstract][Full Text] [Related]
18. A biological, immunological and physico-chemical comparison of the current clinical batches of the recombinant FSH preparations Gonal-F and Puregon.
Horsman G; Talbot JA; McLoughlin JD; Lambert A; Robertson WR
Hum Reprod; 2000 Sep; 15(9):1898-902. PubMed ID: 10966982
[TBL] [Abstract][Full Text] [Related]
19. Ovarian stimulation during assisted reproduction treatment: a comparison of recombinant and highly purified urinary human FSH. On behalf of The Feronia and Apis study group.
Schats R; Sutter PD; Bassil S; Kremer JA; Tournaye H; Donnez J
Hum Reprod; 2000 Aug; 15(8):1691-7. PubMed ID: 10920087
[TBL] [Abstract][Full Text] [Related]
20. Retrospective analysis of the use of two recombinant follitropin alfa injections in patients undergoing in vitro fertilization treatment with the gonadotropin-releasing hormone antagonist protocol.
Šprem Goldštajn M; Dumančić S; Mikuš M
J Obstet Gynaecol Res; 2021 Mar; 47(3):992-1001. PubMed ID: 33372397
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
